Robeco Institutional Asset Management B.V. Bei Gene, Ltd. Transaction History
Robeco Institutional Asset Management B.V.
- $66.7 Billion
- Q3 2025
A detailed history of Robeco Institutional Asset Management B.V. transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Robeco Institutional Asset Management B.V. holds 668 shares of BGNE stock, worth $151,442. This represents 0.0% of its overall portfolio holdings.
Number of Shares
668Holding current value
$151,442% of portfolio
0.0%Shares
8 transactions
Others Institutions Holding BGNE
# of Institutions
291Shares Held
31.6MCall Options Held
95.8KPut Options Held
147K-
Baker Bros. Advisors LP New York, NY8.8MShares$1.99 Billion16.25% of portfolio
-
Primecap Management CO Pasadena, CA5.08MShares$1.15 Billion0.91% of portfolio
-
Capital International Investors Los Angeles, CA5.05MShares$1.14 Billion0.19% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD1.63MShares$370 Million0.06% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E91.03MShares$234 Million7.05% of portfolio
About BeiGene, Ltd.
- Ticker BGNE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,700,000
- Market Cap $23.5B
- Description
- BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...